GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » Cyclically Adjusted Revenue per Share

HLB Therapeutics Co (XKRX:115450) Cyclically Adjusted Revenue per Share : ₩751.71 (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

HLB Therapeutics Co's adjusted revenue per share for the three months ended in Mar. 2025 was ₩183.406. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩751.71 for the trailing ten years ended in Mar. 2025.

During the past 12 months, HLB Therapeutics Co's average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of HLB Therapeutics Co was -9.50% per year. The lowest was -11.80% per year. And the median was -11.30% per year.

As of today (2025-06-01), HLB Therapeutics Co's current stock price is ₩8060.00. HLB Therapeutics Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩751.71. HLB Therapeutics Co's Cyclically Adjusted PS Ratio of today is 10.72.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HLB Therapeutics Co was 18.37. The lowest was 3.71. And the median was 8.83.


HLB Therapeutics Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for HLB Therapeutics Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co Cyclically Adjusted Revenue per Share Chart

HLB Therapeutics Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,022.59 991.81 724.84 713.62 736.27

HLB Therapeutics Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 715.37 718.03 728.15 736.27 751.71

Competitive Comparison of HLB Therapeutics Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, HLB Therapeutics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Therapeutics Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's Cyclically Adjusted PS Ratio falls into.


;
;

HLB Therapeutics Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HLB Therapeutics Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=183.406/122.5900*122.5900
=183.406

Current CPI (Mar. 2025) = 122.5900.

HLB Therapeutics Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 88.831 100.051 108.843
201509 88.930 100.111 108.899
201512 108.878 100.220 133.180
201603 103.946 100.561 126.717
201606 82.750 100.791 100.647
201609 97.719 101.461 118.069
201612 75.611 101.561 91.267
201703 87.397 102.851 104.170
201706 78.949 102.611 94.321
201709 119.671 103.491 141.757
201712 70.183 102.991 83.539
201803 83.093 104.101 97.851
201806 68.887 104.130 81.099
201809 407.728 105.651 473.101
201812 270.338 104.351 317.590
201903 166.918 104.491 195.830
201906 163.418 104.881 191.011
201909 383.707 105.200 447.134
201912 409.982 105.121 478.111
202003 166.926 105.354 194.235
202006 125.221 105.112 146.043
202009 176.219 106.198 203.420
202012 258.652 105.765 299.797
202103 119.643 107.357 136.619
202106 92.186 107.579 105.050
202109 309.257 108.759 348.585
202112 188.163 109.676 210.318
202203 153.112 111.848 167.817
202206 73.610 114.072 79.106
202209 349.425 114.715 373.411
202212 105.605 115.179 112.400
202303 175.366 116.507 184.521
202306 111.542 117.182 116.690
202309 249.432 118.964 257.036
202312 202.482 118.837 208.876
202403 164.804 120.123 168.188
202406 149.142 120.007 152.352
202409 177.652 120.861 180.193
202412 193.535 121.135 195.859
202503 183.406 122.590 183.406

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


HLB Therapeutics Co  (XKRX:115450) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HLB Therapeutics Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8060.00/751.71
=10.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HLB Therapeutics Co was 18.37. The lowest was 3.71. And the median was 8.83.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


HLB Therapeutics Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Therapeutics Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co Headlines

No Headlines